Joseph Jacob, MD, discusses the promising impact of TAR-200.

BOSTON & MONTREAL, June 25, 2025--enGene Holdings Inc. (Nasdaq: ENGN, or "enGene" or the "Company"), a clinical-stage, non-viral gene-based immunotherapy company, today announced that the U.S. Food ...

Scientists have found a novel way that includes a new lab-grown material that could help slow and even reverse some of the ...

The US Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to detalimogene voraplasmid (previously known as EG-70), Canadian company enGene’s lead ...

Ferring Pharmaceuticals officially opened doors to its state-of-the-art gene therapy manufacturing facility in Parsippany ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

CG Oncology, Inc.'s promising bladder cancer therapy, strong financials, and unique therapeutic profile make it a compelling ...

The Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to detalimogene voraplasmid for the treatment of high-risk, Bacillus Calmette-Guérin ...

Protara Therapeutics, Inc. (Nasdaq: TARA) (“Protara” or the “Company”), a clinical-stage company developing transformative ...

As part of the mission, Shubhanshu Shukla becomes the second Indian to go to space after Rakesh Sharma and will also soon ...

enGene Holdings shares were up 7% to $3.25 after the company said that the Food and Drug Administration has granted Regenerative Medicine Advanced Therapy designation to detalimogene voraplasmid.

Researchers have found in a phase 3 trial that phentolamine ophthalmic solution 0.75% led to significant improvements in mesopic low contrast distance visual acuity and patient-reported ...